Tokyo, June 18 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000058084) titled 'Drug use-results survey of TECVAYLI Subcutaneous Injection in patients with relapsed or refractory multiple myeloma (limited to patients who are refractory to standard treatments)' on June 16.
Study Type:
Observational
Primary Sponsor:
Institute - Janssen Pharmaceuticals K.K.
Condition:
Condition - relapsed or refractory multiple myeloma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - This survey aims to investigate the risk factors of immune effector cell-associated neurotoxicity syndrome (Hereinafter referred to as ICANS) and to investigate the safety of Tec...